Collectively, these sets of comprehensive investigations collective support higher tumor breakdown and higher anti‐tumor immune function of DR5 agonists when given in combination of ROCK1 inhibitors or PD‐L1 function inhibiting antibodies. The gene discussed is ROCK1; the disease is neoplasm.